Zai Lab Ltd ADR (ZLAB) Stock Price, Quote & News

Company Profile

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for commu...

Industry: Biotechnology

Sector: Healthcare

Phone: 86 21 6163 2588

Website: www.zailaboratory.com

Address:

Building B, 899 Halei Road, Pudong, China

Spartrap Jan. 13 at 11:48 PM

$ZLAB Q&A session at JPM was crazy sharp. Analysts really starting to take notice

0 · Reply

Spartrap Jan. 13 at 4:09 PM

$ZLAB incredible pipeline. Look at the depth of it. This has to be one of the most deeply mispriced security in the entire market. After 8 years of analysing and investing in biotechs, it is the first time I actively recommend a name to my closest friends and family

0 · Reply

Spartrap Jan. 13 at 1:48 PM

$ZLAB https://ir.zailaboratory.com/news-releases/news-release-details/zai-lab-highlights-strategic-priorities-and-global-pipeline

0 · Reply

Spartrap Jan. 9 at 8:11 PM

$ZLAB always the same pattern, with a shorting algo fading out early rallies. Anyways, +$1 per week for the next 5 years is fine I guess :')

0 · Reply

Spartrap Jan. 7 at 2:01 PM

$ZLAB factoring in new approvals, I reckon the 2B rev projection is still very much in play and in ye 2028 ZLAB as good chances of trading at $20-25B MC. 5 years out with ADCs, I see $60B. 8 yrs out and it will be a peer of BeiGene. If you wait till 2028 to invest, you'll still have a x7 investing opportunity into a booming business. But if you buy it right now, that's a +7000% op at an incredibly low risk. NFA. GL. Madly

0 · Reply

Spartrap Jan. 7 at 2:14 AM

$ZLAB meanwhike HK is humming along, ignoring ADR bearishness. Upcoming rally is going to rip our collective face off. Only serious risk I see at this point is systemic business disruption from one pitiful orange fascist warmonger with alzheimer. Moving my zlab from ADR to Tradegate as we speak to mitigate.. GL.

0 · Reply

Spartrap Jan. 6 at 6:32 PM

$ZLAB only huge news here and the market continues to shrug it off. Patience!

1 · Reply

rubraquercus Jan. 6 at 5:49 PM

$ZLAB https://zailab.gcs-web.com/zh-hant/news-releases/news-release-details/zai-lab-announces-national-medical-products-administration-nmpa

0 · Reply

BillionerOfKing Jan. 3 at 4:57 AM

$ZLAB Current Stock Price: $17.34 Contracts to trade: $20 ZLAB Jan 16 2026 Call Entry: $0.42 Exit: $0.64 ROI: 51% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

pierke Jan. 1 at 1:12 PM

$ZLAB happy new year hopefully a great year ahead

0 · Reply

Zai Lab Limited (ZLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 8:00 AM EST - 1 day ago

Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:30 AM EST - 8 days ago

Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors

Jan 5, 2026, 7:30 AM EST - 9 days ago

Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 23, 2025, 7:30 AM EST - 22 days ago

Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia

Dec 8, 2025, 7:00 AM EST - 5 weeks ago

Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis

Dec 7, 2025, 12:11 AM EST - 5 weeks ago

Zai Lab Announces Updates to China's National Reimbursement Drug List

Nov 11, 2025, 12:00 PM EST - 2 months ago

Zai Lab Limited: Declining Despite Making Progress - I See Opportunity (Reiterate Buy)

Nov 7, 2025, 8:16 AM EST - 2 months ago

Zai Lab Limited (ZLAB) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:00 AM EST - 2 months ago

Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates

Oct 31, 2025, 7:30 AM EDT - 2 months ago

Zai Lab Announces Participation in Investor Conferences in November and December 2025

Oct 24, 2025, 2:37 PM EDT - 2 months ago

Zai Lab Limited (ZLAB) Discusses Updated Monotherapy Phase I Data for Suzhou and Outlines Next Steps in Clinical Development Transcript

Oct 24, 2025, 9:00 AM EDT - 2 months ago

Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study

Oct 15, 2025, 7:30 AM EDT - 3 months ago

Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025

Oct 13, 2025, 12:02 PM EDT - 3 months ago

Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

Sep 11, 2025, 8:02 AM EDT - 4 months ago

Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback

Sep 9, 2025, 6:47 PM EDT - 4 months ago

Zai Lab Limited (ZLAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 1, 2025, 8:00 PM EDT - 4 months ago

Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong

Aug 28, 2025, 7:30 AM EDT - 4 months ago

Zai Lab Announces Participation in Investor Conferences in September 2025

Aug 19, 2025, 7:30 AM EDT - 5 months ago

Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer

Aug 13, 2025, 11:00 AM EDT - 5 months ago

Zai Lab Establishes Oncology Scientific Advisory Board

Aug 7, 2025, 10:29 PM EDT - 5 months ago

Zai Lab Limited (ZLAB) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 6:00 AM EDT - 5 months ago

Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates

Jul 10, 2025, 7:30 AM EDT - 6 months ago

Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025

Jun 30, 2025, 9:05 AM EDT - 7 months ago

Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer

Jun 13, 2025, 7:00 AM EDT - 7 months ago

Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025

Jun 2, 2025, 7:00 AM EDT - 8 months ago

Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

May 31, 2025, 3:08 PM EDT - 8 months ago

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

NVCR

May 30, 2025, 7:30 AM EDT - 8 months ago

Zai Lab Announces Participation in Investor Conferences in June 2025

May 28, 2025, 2:48 AM EDT - 8 months ago

Zai Lab Limited Is Well Positioned For Long-Term Growth

May 22, 2025, 11:25 AM EDT - 8 months ago

Zai Lab Limited: Banking On Chinese Pharma Growth

May 19, 2025, 7:00 AM EDT - 8 months ago

Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer

May 11, 2025, 8:55 AM EDT - 8 months ago

Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript

May 8, 2025, 6:00 AM EDT - 8 months ago

Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates

Apr 25, 2025, 1:12 PM EDT - 9 months ago

Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025

Apr 23, 2025, 10:56 AM EDT - 9 months ago

Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting

Apr 21, 2025, 7:30 AM EDT - 9 months ago

Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors

Mar 26, 2025, 7:00 AM EDT - 10 months ago

Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting

Mar 21, 2025, 5:16 PM EDT - 10 months ago

Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth

Mar 20, 2025, 1:05 PM EDT - 10 months ago

Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks

Mar 12, 2025, 7:30 PM EDT - 10 months ago

Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer

Mar 3, 2025, 7:30 AM EST - 11 months ago

Zai Lab Announces Participation in Investor Conferences in March 2025

Feb 27, 2025, 10:46 PM EST - 11 months ago

Zai Lab Limited (ZLAB) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 6:00 AM EST - 11 months ago

Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates

Jan 28, 2025, 7:30 AM EST - 1 year ago

Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025

Jan 22, 2025, 11:15 PM EST - 1 year ago

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)

Jan 17, 2025, 7:30 AM EST - 1 year ago

Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia

Jan 15, 2025, 7:30 AM EST - 1 year ago

Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer

Jan 10, 2025, 7:30 AM EST - 1 year ago

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

VRTX

Spartrap Jan. 13 at 11:48 PM

$ZLAB Q&A session at JPM was crazy sharp. Analysts really starting to take notice

0 · Reply

Spartrap Jan. 13 at 4:09 PM

0 · Reply

Spartrap Jan. 13 at 1:48 PM

$ZLAB https://ir.zailaboratory.com/news-releases/news-release-details/zai-lab-highlights-strategic-priorities-and-global-pipeline

0 · Reply

Spartrap Jan. 9 at 8:11 PM

$ZLAB always the same pattern, with a shorting algo fading out early rallies. Anyways, +$1 per week for the next 5 years is fine I guess :')

0 · Reply

Spartrap Jan. 7 at 2:01 PM

0 · Reply

Spartrap Jan. 7 at 2:14 AM

0 · Reply

Spartrap Jan. 6 at 6:32 PM

$ZLAB only huge news here and the market continues to shrug it off. Patience!

1 · Reply

rubraquercus Jan. 6 at 5:49 PM

$ZLAB https://zailab.gcs-web.com/zh-hant/news-releases/news-release-details/zai-lab-announces-national-medical-products-administration-nmpa

0 · Reply

BillionerOfKing Jan. 3 at 4:57 AM

0 · Reply

pierke Jan. 1 at 1:12 PM

$ZLAB happy new year hopefully a great year ahead

0 · Reply

Spartrap Dec. 29 at 4:31 PM

$ZLAB inclusion of KarXT in the China Schizophrenia treatment Guidelines 2025 ahead of approval is a *huge* headstart that is poorly understood. Such guidelines aren't typically reassessed very often. I remember when Rigel missed the cut to make it in the 2019 ITP guidelines for Tavalisse in the US, and had to painstakingly row against a very powerful tide of entrenched steroid practice. Rigel is doing OK nowadays but it's been a major loss for investors

2 · Reply

Spartrap Dec. 24 at 5:16 PM

$ZLAB perfect bounce off the lows. Bonus points for the utter stupidity of the ADR crowd👌🏻🔥

0 · Reply

Akwaba76 Dec. 23 at 4:54 PM

$ZLAB 🔥 The market is short-term, science is long-term. COBENFY’s non-dopamine MOA is the biggest innovation in schizophrenia in decades. SP volatility is noise — this is a franchise drug

0 · Reply

Spartrap Dec. 23 at 4:14 PM

$ZLAB hey folks, any thoughts on the apparent deprioritization of adagrasib (Krazati)? There were big hopes at some point IIRC and BMS (having BO Mirati since) has touted P3 confirmatory trial success since then in NSCLC. Yet Zai Lab still has to file for NMPA application it seems, and it doesn't appear anymore in the slide deck. I wonder why?

1 · Reply

DonCorleone77 Dec. 23 at 2:16 PM

$NVO $HII $SOC $ZIM $ZLAB PRE-MARKET MOVERS: Currently Higher: - Sable Offshore (SOC) up 19.2% after the Pipeline Hazardous Materials Safety Administration granted approval of the Las Flores Pipeline restart - Novo Nordisk (NVO) up 9.3% after Reuters reported the company's newly approved version of Wegovy in pill form is planned to go straight to U.S. self-pay channels in early January - HII (HII) up 1.6% after The Wall Street Journal reported on President Trump announcing that the U.S. Navy intends to build a new "Trump-class" battleship as part of the "Golden Fleet" initiative - ZIM Integrated (ZIM) up 7.9% after update on strategic review process - Zai Lab (ZLAB) up 2.0% after announcing that China's National Medical Products Administration approved the new drug application for Cobenfy for the treatment of schizophrenia in adults Currently Lower: - Johnson & Johnson (JNJ) down 0.9% after Reuters reported a Baltimore jury has ordered the company and its subsidiaries to pay more than $1.5B to a woman who said exposure to asbestos in the company's talc-based products caused her peritoneal mesothelioma

0 · Reply

DonCorleone77 Dec. 23 at 2:13 PM

0 · Reply

Spartrap Dec. 23 at 2:09 PM

$ZLAB FYI $BMY spent $14B in 2024 to acquire Karuna therapeutics for Cobenfy (KarXT). Zai Lab was much smarter and acquired the rights for Asia in 2021 so they got an excellent deal, with royalties in the low teens and modest milestone payments. Future blockbuster and you can buy it here for pennies!

1 · Reply

Spartrap Dec. 23 at 2:04 PM

$ZLAB excellent. Just in time to deepen the reversal

0 · Reply

Akwaba76 Dec. 23 at 1:34 PM

$ZLAB Merry X-mas https://www.businesswire.com/news/home/20251223179134/en/Zai-Lab-Announces-Approval-of-COBENFY-xanomeline-and-trospium-chloride-in-China-a-First-in-Class-Therapy-for-Schizophrenia

0 · Reply

Daniels_ Dec. 20 at 4:20 PM

$ZLAB China biotech tracking local sentiment, you need cross border volume and a breakout through resistance before leaning long

0 · Reply

Spartrap Dec. 16 at 6:41 PM

$ZLAB watching this like a hawk. Terrible chart but it makes no sense. Just the Vyvgart licence is worth 10-15% of ARGX MC. Capitulation should be close

1 · Reply

pierke Dec. 16 at 4:01 PM

$ZLAB dirtcheap bought some more

0 · Reply

Market Cap	2.06B
Revenue (ttm)	398.99M
Net Income (ttm)	-257.10M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-64.44%
Debt to Equity Ratio	0.27

Volume	694,700
Avg Vol	894,594
Day's Range	N/A - N/A
Shares Out	111.96M
Stochastic %K	72%
Beta	0.83
Analysts	Strong Sell
Price Target	$45.81